TRAJENTA Film-coated tablet Ref.[7299] Active ingredients: Linagliptin

Source: European Medicines Agency (EU)  Revision Year: 2018  Publisher: Boehringer Ingelheim International GmbH, Binger Str. 173, D-55216 Ingelheim am Rhein, Germany

Product name and form

Trajenta 5 mg film-coated tablets.

Pharmaceutical Form

Film-coated tablet (tablet).

8 mm diameter round, light red film-coated tablet debossed with “D5” on one side and the Boehringer Ingelheim logo on the other.

Qualitative and quantitative composition

Each tablet contains 5 mg of linagliptin.

For the full list of excipients, see section 6.1.

Active Ingredient Description
Linagliptin

Linagliptin is an inhibitor of the enzyme DPP-4 (dipeptidyl peptidase 4, EC 3.4.14.5) an enzyme which is involved in the inactivation of the incretin hormones GLP-1 and GIP (glucagon-like peptide1, glucose-dependent insulinotropic polypeptide). These hormones are rapidly degraded by the enzyme DPP-4. Both incretin hormones are involved in the physiological regulation of glucose homeostasis.

List of Excipients

Tablet core:

Mannitol
Pregelatinised starch (maize)
Maize starch
Copovidone
Magnesium stearate

Film coating:

Hypromellose
Titanium dioxide (E171)
Talc
Macrogol (6000)
Iron oxide red (E172)

Pack sizes and marketing

Perforated alu/alu unit dose blisters in cartons containing 10 × 1, 14 × 1, 28 × 1, 30 × 1, 56 × 1, 60 × 1, 84 × 1, 90 × 1, 98 × 1, 100 × 1 and 120 × 1 film-coated tablets.

Not all pack sizes may be marketed.

Marketing authorization holder

Boehringer Ingelheim International GmbH, Binger Str. 173, D-55216 Ingelheim am Rhein, Germany

Marketing authorization dates and numbers

EU/1/11/707/001 (10 × 1 tablets)
EU/1/11/707/002 (14 × 1 tablets)
EU/1/11/707/003 (28 × 1 tablets)
EU/1/11/707/004 (30 × 1 tablets)
EU/1/11/707/005 (56 × 1 tablets)
EU/1/11/707/006 (60 × 1 tablets)
EU/1/11/707/007 (84 × 1 tablets)
EU/1/11/707/008 (90 × 1 tablets)
EU/1/11/707/009 (98 × 1 tablets)
EU/1/11/707/010 (100 × 1 tablets)
EU/1/11/707/011 (120 × 1 tablets)

Date of first authorisation: 24 August 2011

Date of latest renewal: 22 March 2016

Drugs

Drug Countries
TRAJENTA Austria, Australia, Canada, Cyprus, Estonia, Spain, Finland, France, Hong Kong, Croatia, Ireland, Israel, Italy, Lithuania, Netherlands, New Zealand, Poland, Romania, Singapore, Tunisia, Turkey, United Kingdom, South Africa

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.